【摘要】 目的对配体介导的纳米脂质体作为肿瘤疫苗载体的可行性进行评价。方法建立体外树突状细胞(dendritic cells,DC)模型,考察DC对配体介导纳米脂质体的摄取行为;建立S180荷瘤鼠模型,考察配体介导纳米脂质体对荷瘤鼠的免疫效果。结果 DEC205单克隆抗体介导的纳米脂质体能被DC细胞特异性识别,提高摄取效率,同时也能显著抑制肿瘤生长,延长小鼠存活时间,在整个免疫周期内均能保持较高的IL-12和IFN-γ水平,对S180荷瘤鼠具有明显的免疫治疗作用。结论配体介导的纳米脂质体能够产生有效的抗肿瘤免疫应答,可以作为治疗型肿瘤疫苗的载体。更多还原

【Abstract】 Objective To investigate the feasibility evaluation of ligand-mediated nanoliposomes as carries of anti-tumor vaccine.Methods In vitro dendritic cells(DC) cells model was established to investigate uptake behavior of DC cells,and the mice model bearing S180 cancer tumorwas established to evaluate the antitumor immune effect.Results DEC205 Mc Ab mediated nanoliposomes were readily taken up by dendritic cells,and could significantly inhibit tumor growth,prolong the survival time of mice and maintain a high level of IL-12 and IFN-r in all immune period.Conclusions Ligand-mediated nanoliposomes can enhance the anti-tumor immune response and can be used as carriers of anti-tumor vaccines.更多还原